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Abstract
Rationale Working memory impairments in schizophrenia
have been attributed to dysfunction of the dorsolateral pre-
frontal cortex (DLPFC) which in turn may be due to low
DLPFC dopamine innervation. Conventional antipsychotic
drugs block DLPFC D2 receptors, and this may lead to further
dysfunction and working memory impairments. Aripiprazole
is a D2 receptor partial agonist hypothesised to enhance PFC
dopamine functioning, possibly improving working memory.
Objectives We probed the implications of the partial D2 re-
ceptor agonist actions of aripiprazole within the DLPFC dur-
ing working memory. Investigations were carried out in
healthy volunteers to eliminate confounds of illness or medi-
cation status. Aripiprazole’s prefrontal actions were compared
with the D2/5-HT2A blocker risperidone to separate
aripiprazole’s unique prefrontal D2 agonist actions from its
serotinergic and striatal D2 actions that it shares with
risperidone.
Method A double-blind, placebo-controlled, parallel design
was implemented. Participants received a single dose of either
5 mg aripiprazole, 1 mg risperidone or placebo before
performing the n-back task whilst undergoing fMRI scanning.
Results Compared with placebo, the aripiprazole group dem-
onstrated enhanced DLPFC activation associated with a trend
for improved discriminability (d’) and speeded reaction times.
In contrast to aripiprazole’s neural effects, the risperidone
group demonstrated a trend for reduced DLPFC recruitment.
Unexpectedly, the risperidone group demonstrated similar ef-
fects to aripiprazole on d’ and additionally had reduced errors
of commission compared with placebo.
Conclusion Aripiprazole has unique DLPFC actions attribut-
ed to its prefrontal D2 agonist action. Risperidone’s
serotinergic action that results in prefrontal dopamine release
may have protected against any impairing effects of its pre-
frontal D2 blockade.
Keywords Workingmemory . Aripiprazole . Risperidone .
n-Back . Dopamine . Dorsolateral prefrontal . Antipsychotic .
Partial agonism . D2
Introduction
Aim and rationale
The aim of this study was to investigate the implications of the
partial dopamine D2 receptor agonist properties of
aripiprazole for the neural basis of workingmemory in healthy
volunteers. Impaired working memory is a core feature of
schizophrenia which is not ameliorated by conventional anti-
psychotic drugs (Forbes et al. 2009). The impairment has been
attributed to an impaired dopamine innervation of the dorso-
lateral prefrontal cortex (DLPFC) (Akil et al. 1999; Davis et
al. 1991; Pycock et al. 1980; Slifstein et al. 2015;Winterer and
Weinberger 2004), a key component of the neural circuitry of
working memory. There has been much clinical interest in the
possibility that the partial agonist actions of aripiprazole might
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restore D2 neurotransmission to a low optimal level in prefron-
tal cortex in schizophrenia (Bolonna and Kerwin 2005). This
would preserve or enhance working memory while antipsy-
chotic effects are achieved by preventing overstimulation of
D2 receptors in striatum. We investigated the effects of
aripiprazole on the performance of a working memory task
and its neural correlates using functional magnetic resonance
imaging (fMRI). We compared the effects of aripiprazole with
those of risperidone since both drugs have high affinity for the
D2 receptor combined with serotonergic effects although ris-
peridone lacks the intrinsic D2 agonist activity of aripiprazole.
Dopamine modulation of DLPFC and working memory
Working memory (WM) refers to the ability to hold and man-
age information ‘online’ over short periods of time, allowing
its manipulation and usage in reasoning, comprehension and
decision-making (Levy and Goldman-Rakic 2000).
Numerous neuroimaging studies have shown that a network
of cortical regions centred on the DLPFC is activated by per-
formance of WM tasks such as the n-back task (see below).
Impaired WM performance in patients with schizophrenia is
associated with reduced DLPFC activation compared to con-
trols (Carter et al. 1998; Perlstein et al. 2001; Weinberger et al.
1986). This is thought to reflect cortical inefficiency because
greater DLPFC activation is elicited in patients when perfor-
mance matches control levels (Callicott et al. 2000; Manoach
et al. 1999, 2000).
Dopamine has an important role in WM performance in
both non-human primates (Brozoski et al. 1979; Sawaguchi
2001; Sawaguchi et al. 1990) and in human volunteers (Egan
et al. 2001). Dopamine modulates PFC activity by both D1
(Seamans and Yang 2004) and D2 receptor actions on pyra-
midal cells and interneurons (Wang et al. 2004), which influ-
ence different functional aspects of WM in experimental ani-
mals (Durstewitz and Seamans 2008; Seamans and Yang
2004). Studies in humans suggest a role for D2 receptors in
working memory (Kimberg et al. 1997; Luciana et al. 1992;
Luciana and Collins 1997; Mehta et al. 1999, 2001) although
it is unknown whether these effects are driven by striatal or
cortical D2 receptor actions given the systemic drug adminis-
tration of these studies.
The foregoing evidence suggests that dysregulation of the
DLPFC may contribute to the executive functioning impair-
ments seen in schizophrenia and that impaired dopamine func-
tion could be a key mechanism. The actions of antipsychotic
drugs on dopamine function within the dorsolateral prefrontal
cortex are therefore of considerable interest.
Neurochemical profiles of aripiprazole and risperidone
Aripiprazole is an atypical antipsychotic with a very high af-
finity (0.34 nM) (Burris et al. 2002) for the D2 receptor. In
contrast to all currently available antipsychotic drugs,
aripiprazole has a partial agonist effect on the D2 receptor with
a range of intrinsic efficacies dependent upon the G protein-
coupled receptor system it is acting upon (Lawler et al. 1999;
Shapiro et al. 2003). Because of its high D2 affinity,
aripiprazole is thought to clamp synaptic dopamine function
at a constant but sub-maximal level of activation regardless of
local dopamine concentration. This results in functional an-
tagonism in areas of high dopamine concentration such as
within the striatum. However, in areas of low dopamine con-
centration such as prefrontal cortex, aripiprazole’s partial
agonism would exceed the local action of dopamine
(Bolonna and Kerwin 2005; Grunder et al. 2003) resulting in
increased D2 function. In addition to direct effects at D2 re-
ceptors, aripiprazole has been shown to increase dopamine
release into the mouse prefrontal cortex in in-vivo microdial-
ysis studies (Li et al. 2004; Zocchi et al. 2005). This effect may
be due to the 5-HT1A receptor partial agonism (Ki=3.4 nM)
and the 5-HT2A antagonism (Ki=4.2 nM) that aripiprazole
also possesses (Stark et al. 2007) as both of these actions have
been shown to increase prefrontal dopamine release (Li et al.
2004). Therefore, aripiprazole may also indirectly increase D1
neurotransmission during working memory by increasing pre-
frontal dopamine levels.
Risperidone has a high affinity for D2 receptors but acts as a
pure antagonist. Furthermore, risperidone, like aripiprazole,
increases dopamine release in the prefrontal cortex (Kuroki
et al. 1999) and is a high-affinity 5-HT2A receptor antagonist
(Ki=0.15–0.4 nM) (Leysen et al. 1994; Richelson and Souder
2000). By comparing the two drugs, we aimed to isolate
aripiprazole’s D2 agonist effects from other actions that it
shares with risperidone. This allowed us to separate out the
functional importance of cortical versus striatal D2 receptors
in working memory as both drugs reduce striatal D2 neuro-
transmission but only aripiprazole is hypothesised to have
partial agonist effects at prefrontal D2 receptors. We
hypothesised that aripiprazole would enhance or change pre-
frontal cortex WM activations in relation to improved perfor-
mance compared to placebo and risperidone.
Methods
Participants
This study was approved by the NHS Research Ethics
Committee and the Committee on the Ethics of Research on
Human Beings of the University of Manchester. The study
was therefore performed in accordance with the ethical stan-
dards laid down in the 1964 Declaration of Helsinki. Male
participants were recruited via e-mail and were paid for their
participation. Participants had to meet the following criteria:
healthy according to physical examination including blood
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pressure, kidney and liver function tests and blood glucose
levels, general health questionnaire and electrocardiography.
Participants had no current diagnosis, or history of, psychiatric
illness or substance use disorder. Participants were not taking
any medication, were non-smokers and were right handed.
Participants consumed under 20 units of alcohol a week and
were asked to remain abstinent from alcohol and caffeine for
24 h prior to the study; compliance was self-reported.
Screening procedures included the Quick Test (Ammon
and Ammons 1962) to provide an estimate of IQ, Mini
International Neuropsychiatric Interview (MINI) (Sheehan et
al. 1998), and the Edinburgh Handedness Inventory
(EHI) (Oldfield 1971). The mean age (SD) was 23 (4.96),
mean IQ (SD) was 94 (7.96), and the mean weight (SD) was
68.2 kg (11.6). ANOVAs revealed that there were no signifi-
cant differences in age (p=0.32), IQ (p=0.97) or weight
(p = 0.39) of the participants assigned to the placebo,
aripiprazole or risperidone drug group. Urine drug tests, elec-
trocardiograms (ECG) and blood tests were carried out at
screening and any participants with a positive result and/or
abnormal ECG reading or blood results were excluded from
the study. Written informed consent was obtained from the
participants before enrolment to the study.
Experimental design and procedures
The study was performed following a randomised, double-
blind, placebo-controlled, parallel group procedure. This par-
allel group design was chosen over a within-subject design to
avoid practice effects on n-back performance and habituation
effects to both the scanner environment and n-back task.
Interactions between these effects and drug effects would
make results difficult to interpret. Thirty-seven participants
took part in the study in total: 13 participants received an acute
oral dose of 5 mg aripiprazole, 12 received 1 mg risperidone,
and 12 received placebo. Scanner technical problems resulted
in loss of data from three participants (1 placebo, 1
aripiprazole, 1 risperidone). Therefore, three participants were
excluded prior to any group analysis. The doses were subther-
apeutic, chosen to minimise side effects in healthy volunteers.
Recent studies have examined aripiprazole receptor occupan-
cy in healthy volunteers after acute doses of aripiprazole; one
study demonstrated that 5 mg of aripiprazole resulted in a
mean striatal D2 occupancy of 55 % (Kim et al. 2012).
Another study reported 74 % striatal and 51 % frontal D2
occupancy after 6 mg of aripiprazole (Takahata et al. 2012).
A single 1 mg dose of risperidone results in striatal D2 occu-
pancies of 50 % in healthy volunteers (Nyberg et al. 1993).
Whilst this study did not measure extrastriatal D2 occupancy,
PET studies assessing frontal occupancy after a single dose of
2 mg risperidone, and continuous dosing of 1 mg risperidone,
suggest that frontal D2 occupancies of risperidone, whilst
being slightly lower, do not differ significantly from striatal
D2 occupancies (Agid et al. 2007; Ito et al. 2009). Taken
together, it may be assumed that similar frontal D2 occupan-
cies of slightly below 50%were achievedwith single doses of
5 mg aripiprazole and 1 mg risperidone.
Participants were scanned 3.5 h after taking the test drug as
this represents the tmax for aripiprazole (Kubo et al. 2007).
The tmax for risperidone and its equally potent metabolite is
1.5 and 3 h, respectively (Ereshefsky 1996; Huang et al.
1993). Participants were assessed for medication side effects
by the on-site study clinician. Upon leaving the scanner, blood
pressure was taken both standing and sitting and participants
were assessed once more before being allowed to leave.
N-back task
The task was programmed using E-Prime v1.1.4.4. SP3
(Psychology Software Tools 2003). Stimuli were presented
in a block design, with three different conditions presented
in 26-s blocks. For the 0-back condition, participants viewed
a series of 13 letters which were presented with an interstim-
ulus interval of 2 s (letter presented for 1500 ms followed by a
blank screen for 500 ms). Participants were asked to respond
with a button press on a button box whenever they saw an ‘X’
appear on the screen, this condition does not require any work-
ing memory processing and therefore represents the control
condition for the task. For the 1-back condition, participants
were asked to respond when they saw a letter which was the
same as the last one presented. For the 2-back condition, par-
ticipants were asked to respond when they saw a letter on
screen that was the same as the one presented before the last
letter. To avoid potential ceiling effects, participants were not
permitted to practise the task although they received detailed
task instructions and it was ensured they understood each task
condition before entering the scanner. Thirteen letters were
presented in each test block and each block contained three
target stimuli. The task comprised three 2-back blocks, three
1-back blocks and six 0-back blocks presented in a pseudo-
randomised order with a block of the 0-back condition pre-
sented between each 1-back and 2-back block. Whilst in the
scanner, participants were instructed on the type of block they
were about to perform by verbal instructions presented on the
screen for 9 s.
Missed targets were recorded as omission errors (OEs),
whereas participants’ responses to non-targets were recorded
as commission errors (CEs). There were a total of 9 target
letters for the 1-back and 2-back condition and 18 target letters
for the 0-back condition. The task lasted 7 min.
Statistical analysis of behavioural data
Participants made few errors of commission or omission.
Chi-square tests (likelihood ratio; Lχ2) were used to
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assess whether there was an association between the drug
taken and the frequency of OEs and CEs made for the 0-
(baseline), 1- and 2-back conditions. Furthermore, dis-
criminability or d prime (d’) was assessed. Hit rate was
defined as the proportion of the targets responded to and
the false alarm (FA) rate was the proportion of non-targets
responded to. The hit rate and false alarm rate were trans-
formed to Z-values using the NORMSINV function in
excel (Haatveit et al. 2010). d’ is calculated with the fol-
lowing formula: Zhit−ZFA. Perfect hit rate or FA rates of 1
or 0 respectively were converted using the following for-
mulas before the Z-transform was carried out; proportions
of 1 were converted to 1− 1/(2N) and proportions of 0
were converted to 1/(2N) (Haatveit et al. 2010). A mixed
ANCOVA using SPSS was carried out (n-back level and
drug group as the within- and between-subject factor re-
spectively) with the d’ score for the 0-back condition
(which does not measure working memory but indexes
attentional processing) added as a mean centred covariate.
Statistical analyses were carried out using SPSS v22. A
mixed ANCOVA (n-back level and drug group as the
within and between group factor respectively) was used
to investigate drug effects on reaction times for correct
responses for the 1-back and 2-back levels. To control
for individual differences in motor responses, the reaction
times for correct responses on the 0-back condition were
entered as a mean centred covariate in the analysis. For d’
and reaction time analyses, main effects of group were
investigated with Sidak post hoc tests, and drug group
by n-back level interactions were investigated with both
paired and two-sample t tests. A one-way ANOVA was
carried out on the 0-back condition to test for any effects
of the drugs on attentional processing.
Due to technical problems with recording responses, re-
sponse data was lost from 3 out of the 12 participants in the
aripiprazole group and a further 1 from the 11 participants in
the placebo group; therefore, behavioural data from 9 partic-
ipants from the aripiprazole group, 10 from the placebo group
and 11 from the risperidone group were entered into the be-
havioural analysis.
Image acquisition of functional data
Whole brain T2*-weighted images were acquired on a 3 T
Philips Achieva scanner with single shot, gradient echo-
p lanar imaging wi th the fo l lowing paramete rs :
FOV = 230 mm, acquisition matrix = 128 × 128, TR/TE
2000/35 ms, voxel size = 1.8 × 1.8 × 3.0 mm, 0.5-mm slice
gap, and 34 slices. T1-weighted structural images were ac-
quired for each participant in order to exclude patients with
any anatomical abnormalities and for use during the prepro-
cessing of functional images.
Preprocessing and analysis of fMRI data
F ina l g r oup s i z e f o r fMRI da t a ana l y s i s wa s
12 for aripiprazole, 11 for risperidone and 11 for placebo.
The functional images were converted from the PARREC for-
mat to the analyse format using MRIcro (version 1.40).
Functional data were analysed using Statistical Parametric
Mapping (SPM12; The Wellcome Department of Cognitive
Neurology, London, England) implemented in Matlab
(R2013a).
Images were realigned to correct for motion artefacts,
and the T1 structural image was coregistered with the
mean image of the realigned functional images. The T1
structural image was segmented and normalised using
t issue probabi l i ty templates suppl ied by SPM.
Normalisation parameters were then applied to the func-
tional images. Images were smoothed using a Gaussian
k e r n e l o f t h e f o l l o w i n g d i m e n s i o n s
5.4 mm×5.4 mm×10.5 (three times the voxel size).
First-level analysis
Data were fitted via general linear modelling in SPM (0-
back, 1-back and 2-back conditions). The input model
was convolved with the haemodynamic response func-
tion (HRF) in order to provide a better fit of the data
(Smith 2001). The low-frequency drifts in the data were
modelled out using a high pass filter set to 140 s, equiv-
alent to two times the main repetition time of the task.
The following contrasts were specified: 1-back minus 0-
back, 2-back minus 0-back, 1-back&2-back minus 0-
back and 2-back minus 1-back. Movement outliers
(scan to scan displacement of >2 mm or volumes with
global brain activation >3 standard deviations away from
the mean) were detected using Artifact Detection Tools
(ART) (http://www.nitrc.org/projects/artifact_detect/), and
these outliers were added as nuisance regressors to the
first-level model. All participants had less than 10 % of
volumes detected as outliers.
Second level analysis
As fMRI packages only produce one error term during statis-
tical analysis, statistical tests containing both within- and
between-subject factors within a single model are not validly
performed (McLaren DG et al. 2011). For this reason, separate
models were used for both within- and between-subject fac-
tors. To assess the effect of the n-back task and main effect of
drug group, an ANOVAwas specified with the average of the
1-back and 2-back condition (compared to 0-back) as a factor.
To assess main effect of n-back level and n-back level by drug
group interactions, anANOVAwas specified containing the 2-
back minus 1-back contrast as a factor. Cluster thresholding
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was used with a cluster forming thresholded of p<0.005. For
the main effects of task and n-back level in all 34 participants,
a whole-brain family-wise error cluster threshold of p<0.05
was applied (pFWEc<0.05). Assessments of drug group ef-
fects and n-back level by drug group interactions were con-
fined to a DLPFC region of interest and thresholded at
pFWEc<0.05 small volume corrected (SVC). The DLPFC
region of interest (ROI) comprised of a sphere of 10-mm ra-
dius centred around the Talairach coordinates (42, 32, 30)
representing the peak DLPFC activation generated from a
meta-analysis of verbal, identity-monitoring n-back task data
in healthy controls (Owen et al. 2005). Furthermore, ROI
analysis was carried out with and without a mask of the pos-
itive main effect of the n-back task (pFWEc<0.05) to deter-
mine whether the drug effects occurred within regions activat-
ed by the task. The average of the beta-estimates were extract-
ed from clusters significant for drug group effects (main ef-
fects or interactions) and plotted. Effects significant in the
ANOVA were investigated with post-hoc two-sample t test
comparisons.
To determine if any of the drug effects on brain activation
influenced the behavioural measures, correlational analyses
were carried out between BOLD signal change within the 1-
back and 2-back conditions compared to 0-back and the be-
havioural measures (CE, OE, d’ and reaction time for correct
responses), using any clusters showing significant drug effects
as regions of interest. This was carried out within each drug
group individually and with all participants from all three drug
groups together.
Results
Tolerability
The medications were well tolerated. Mild nausea was report-
ed by one participant taking aripiprazole although this was
temporary and the participant was able to carry out the scan.
There were no other adverse reactions to the medications, and
no participants were excluded on the basis of lack of
tolerability.
Behavioural
Omission and commission errors
Most participants made no CEs or OEs in the 0-back and 1-
back condition. This pattern was not modified by drug treat-
ment (Lχ2 not shown). More errors were made in the 2-back
condition but OEs remained unaffected by drug treatment
(Lχ2(6) =9.92, p=0.16; see supplementary materials for fig-
ure). In contrast, CEs at 2-back were affected by drug
treatment (Lχ2(4) =13.723, p=0.013); only 3 of 11 partici-
pants treated with risperidone made CEs compared with 9/
10 placebo and 7/9 aripiprazole treated participants.
Discriminability d’
There were no significant effects of drug group on the 0-back
condition, F(2,27)=0.60, p=0.55. The mixed ANCOVA re-
vealed a significant effect of n-back, F(1,26) = 31.95,
p<0.001, and a significant drug by n-back level interaction,
F(2,26)=3.45, p=0.047. From Fig. 1, it can be seen that the
main effect is driven by a general lowering of d’scores in the
2-back condition compared to the 1-back condition, reflecting
the greater task difficulty. However. post hoc paired t tests
revealed the interaction to be caused by d’ scores being sig-
nificantly different for the 2-back compared to 1-back for pla-
cebo (p<0.001) and risperidone (p=0.027), but not for the
aripiprazole condition (p=0.223). Furthermore, drug group t
test comparisons at each of the two n-back levels (with 0-back
covariate) revealed a trend for a significant difference between
placebo and aripiprazole (p=0.057) and risperidone and pla-
cebo (p=0.054) for the 2-back condition but not for the 1-
back condition (p>0.1).
Reaction times
There was no significant effect of drug group on reaction
times for correct responses for the 0-back condition, F(2,
27)=0.31, p=0.74, indicating that there were no drug effects
onmotor speed or attention. Themixed ANCOVA revealed an
overall significant effect of the 0-back reaction time covariate,
F(1,26)=25.407, p<0.001, but no covariate by n-back level
interaction, F(1,26)=0.063, p=0.804, indicating that reaction
times for the 0-back condition were significantly related to
reaction times for both the 1-back and the 2-back condition.
Fig. 1 N-back d' scores. Scores shown for the 0-back (baseline condi-
tion), 1-back and 2-back condition for the placebo, aripiprazole and ris-
peridone groups. Error bars indicate standard error of the mean
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The mixed ANCOVA revealed a significant effect of n-back
level F(1,26) =25.4, p<0.001, but no n-back level by drug
interaction, F(2,26)=1.511, p=0.24, indicating that reaction
times slowed with increasing task difficulty although this oc-
curred to the same degree across all treatment groups.
Reaction times were faster after both drugs (notably
aripiprazole) (Fig. 2), but this fell short of full statistical sig-
nificance (F(2,26)=3.006, p=0.07). Sidak post hoc tests re-
vealed a trend for faster reaction time with aripiprazole
(p=0.06) compared with placebo. No trends were found for
the risperidone placebo comparison (p=0.59) nor were there
any trends for significant differences in the aripiprazole versus
risperidone comparison (p=0.44).
fMRI
Positive effect of n-back task and n-back level (cluster
forming threshold of p<0.005, pFWEc<0.05)
The n-back task (1&2back across all groups) produced signif-
icant activations in the expected cortical areas for working
memory tasks as identified in the normative meta-analysis of
n-back task (Owen et al. 2005). These included the bilateral
DLPFC, the bilateral ventrolateral prefrontal cortex (VLPFC),
the bilateral premotor cortex, the bilateral rostral PFC, the
bilateral cingulate gyri and the bilateral inferior and superior
parietal cortices (Fig. S1 included in supplementary mate-
rials). Furthermore, all regions were recruited to a greater de-
gree in the 2-back condition compared to the 1-back condi-
tion, reflecting the greater task difficulty.
Main effects of drug and drug by n-back level interactions
(cluster forming threshold of p<0.005, pFWEc<0.05,
SVC)
Main effect of drug group was found within the DLPFC with
an extent of 64 voxels at Talairach coordinates (42, 32, 28),
pFWEc=0.008 SVC for the DLPFC ROI. Masking with the
positive effect of task revealed this drug effect to occur entire-
ly within regions activated by the task. Post hoc two-sample t
tests with the DLPFC ROI revealed that this effect was due to
aripiprazole increasing activation within the DLPFC com-
pared to both the risperidone group, pFWEc=0.004 SVC,
and the placebo group, pFWEc=0.027. Compared to the pla-
cebo, there was a trend for a significant decrease with risper-
idone although this fell short of statistical significance,
pFWEc=0.07 SVC (also see Fig. 3)
No n-back level by drug interactions were found indicating
that the drugs had similar effects during the 1-back and the 2-
back conditions.
Correlational analyses
None of the areas produced by the main effect of drug were
found to be positively or negatively correlated with any of the
behavioural measures for the 1-back minus 0-back or the 2-
back minus the 0-back conditions.
Discussion
The aim of this study was to determine whether partial agonist
effects of aripiprazole on dopamine D2 receptors in the pre-
frontal cortex would improve performance of a working mem-
ory task in healthy volunteers in comparison with neutral or
adverse effects of the full D2 receptor antagonist risperidone.
As hypothesised, aripiprazole enhanced activation in the
DLPFC and demonstrated a trend for improved reaction times
and discriminability (d’) compared to placebo. Risperidone
reduced activation within the right DLPFC compared to
aripiprazole with a trend for reduced activation compared to
placebo. However, against our prediction, the risperidone
group had reduced errors of commission and had similar ef-
fects to aripiprazole on d’. Aripiprazole and risperidone have
direct actions at D2 receptors and serotonin receptors, but they
are also expected to have indirect actions at D1 receptors due
to their serotonin receptor–mediated increases in prefrontal
dopamine release (Kuroki et al. 1999; Li et al. 2004).
Therefore, the fMRI and behavioural effects of the study drugs
are discussed in terms of actions at D2, D1, and 5-HT
receptors.
Dopamine modulation of the prefrontal cortex
during working memory
Dopamine is released in the prefrontal cortex during the per-
formance of working memory tasks (Watanabe et al. 1997)
where it acts to modulate the activity of PFC neurons
(Durstewitz et al. 2000; Williams and Goldman-Rakic
1995). Studies have demonstrated that direct application of
Fig. 2 Reaction time for correct responses. Reactions times shown for 0-
back (baseline condition), 1-back and 2-back condition of the n-back task
for the placebo, aripiprazole and risperidone groups. Error bars indicate
standard error of the mean
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D1 (Sawaguchi 2001; Sawaguchi and Goldman-Rakic 1991,
1994) and D2 drugs (Wang et al. 2004) modulate prefrontal
neuronal activity during working memory performance in
non-human primates. Studies in humans demonstrate that
D2 receptors (Kimberg et al. 1997; Luciana and Collins
1997; Luciana et al. 1992; Mehta et al. 1999, 2001;
Tarantino et al. 2011) modulate workingmemory performance
and prefrontal activation (although the striatal vs prefrontal
contribution to these is unknown). Electrophysiological stud-
ies demonstrate that D1 and D2 receptors influence prefrontal
cortex pyramidal neurons in different ways (Seamans and
Yang 2004) which may explain the behavioural and fMRI
effects of aripiprazole and risperidone. Both antipsychotic
drugs cause the release of dopamine into the prefrontal cortex
(Li et al. 2004) therefore, both drugs are expected to have
indirect D1 receptor effects. Given the D2 partial agonist ef-
fects of aripiprazole versus the D2 antagonism of risperidone,
we expect aripiprazole to have both D2- and D1-mediated
agonist PFC actions whereas we expect risperidone’s dopami-
nergic actions to be mediated by D1 receptor agonism.
D2-mediated effects within the prefrontal cortex
during performance of the n-back task
The n-back task requires participants to attend to newly pre-
sented letters whilst maintaining a representation of the letter
that was presented ‘n’ letters back. The letter presented n trials
back quickly becomes irrelevant as the next letter is presented,
and the representation of this letter must be quickly replaced
with newly presented letters. In contrast to delayed response
tasks whereby a single stimulus needs to be maintained over a
delay, items maintained in the n-back task are constantly
changing, and for successful performance, new information
needs to be readily incorporated into the PFC. D2 agonists
have been shown to increase working memory capacity (the
number of new items than can be encoded) whereas D1 effects
are crucial for tasks involving the maintenance of a stimulus
over a delay (Tarantino et al. 2011). D2 and D1 receptors have
oppos ing e f f e c t s on exc i t a to ry and inh ib i t o ry
neurotransmission within the PFC. Studies have shown that
D2 receptors decrease, and D1 receptors increase, NMDA
(Zheng et al. 1999) and GABA currents (Kroener and Lavin
2010; Seamans et al. 2001). According to computational
models, D2 receptors decrease the competition between
groups of neurons within the PFC. These actions facilitate
movement along representations, aiding the fast switching of
attention and incorporation of new information into PFC net-
works (Durstewitz and Seamans 2008). Thus, aripiprazole’s
partial D2 agonism may have contributed to the trends for
speeded reaction time and improved d’. In a study examining
executive functioning in healthy volunteers, the D2 agonist
bromocriptine speeded reaction time in a Stroop task (i.e. de-
creased interference) (Roesch-Ely et al. 2005). The authors
explain this effect in terms of D2-receptor-mediated facilita-
tion of the switching from reading the colour of words to
naming them. Too much D2 to D1 receptor stimulation can
be detrimental to cognitive performance by increasing dis-
tractibility (Durstewitz and Seamans 2008) as demonstrated
by the cognitive impairing effect of the D2 agonist bromocrip-
tine in individuals with a high baseline working capacity who
are hypothesised to have optimum dopamine levels at baseline
but are ‘overdosed’ after bromocriptine administration (Gibbs
and D’Esposito 2005; Kimberg et al. 1997). Therefore, a com-
bination of aripiprazole’s partial, rather than full, D2 agonism,
along with its secondary D1 receptor effects, as aripiprazole
has been shown to reverse cognitive deficits in rodents via D1
receptor agonism (Nagai et al. 2009), may contribute to its
favourable effects on reaction time. Notably, however, a very
recent study assessing the acute effects of 10 mg aripiprazole
on n-back performance in healthy volunteers found contradic-
tory results to the present study in that they reported increased
reaction times with aripiprazole and no change in neural acti-
vation compared to placebo (Goozee et al. 2015). We believe
that dose differences underlie these contradictory findings.
Kim et al. compared resting brain metabolism, receptor occu-
pancy and n-back performance in healthy volunteers taking
various doses of aripiprazole (Kim et al. 2013). They demon-
strated that both 10- and 30-mg doses significantly decreased
Fig. 3 Brain images show the sagittal, coronal and axial views of the
significant DLPFC cluster demonstrating a main effect of drug group (F-
contrast image thresholded at p < 0.005). Histograms demonstrate the
mean BOLD response within this cluster for the different drug groups.
* = comparisons significant at pFWEc < 0.05 SVC for DLPFC in post
hoc tests
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resting brain metabolism whereas 2 and 5 mg of aripiprazole
did not. Furthermore, frontal brain metabolism was found to
be inversely correlated with striatal D2 receptor occupancy
and n-back reaction time. These and our findings suggest a
dose dependency of the cognitive effects of aripiprazole in
healthy volunteers. Doses above 10 mg may have detrimental
effects related to excessive striatal D2 blockade and reduced
frontal metabolism. Doses of 5 mgmay have beneficial effects
which we hypothesise to be due to a combination of D2 and
D1 prefrontal agonism and insufficient striatal D2 blockade to
cause impairment.
Studies in schizophrenia patients support a cognitive en-
hancing role of higher doses (10 mg and above) of
aripiprazole during working memory and verbal cognitive
functioning (Bervoets et al. 2012; Kern et al. 2006; Maat et
al. 2014; Schlagenhauf et al. 2010), although not all studies
support a working memory enhancing role of aripiprazole
(Riedel et al. 2010). Given that schizophrenia is associated
with excessive striatal dopamine transmission (Howes et al.
2012), higher doses of aripiprazole may be tolerated before
striatal D2 neurotransmission is reduced to detrimental levels.
The increased DLPFC activation with aripiprazole may be
due to D2 receptor actions to reduce GABAA inhibition of
pyramidal neurons (Seamans et al. 2001). Whilst D1 receptor
actions can spatially tune activation within the prefrontal cor-
tex by increasing the inhibition of pyramidal neurons
(Williams and Goldman-Rakic 1995), D2 receptor activation
will reduce this inhibition, possibly allowing a greater extent
of DLPFC to be recruited by the task. However, this explana-
tion may be somewhat speculative when considering the
BOLD signal reflects neuronal mass action (Logothetis
2008), whereas the above studies of Williams and Goldman
Rakic and those of Seamans and colleagues report effects in
individual neurons. Furthermore, D2 enhancements of pre-
frontal GABA neurotransmission have also been reported
(Tseng and O’Donnell 2007). The increased BOLD signal in
the DLPFC with aripiprazole was associated with a trend for
faster reaction times and an improvement in d’, arguing
against the suggestion that aripiprazole reduces neuronal effi-
ciency, but rather that this enhancement had a functionally
beneficial effect. This is in agreement with a recent finding
in schizophrenia patients demonstrating greater PFC activa-
tion and improved performance on the n-back task after
switching from typical antipsychotic medications to
aripiprazole (Schlagenhauf et al. 2010).
D1 receptor effects during the n-back task
Against our hypotheses, risperidone had similar effects to
aripiprazole on ‘d, although unlike the aripiprazole group,
this was driven by a reduced tendency to make commis-
sion errors, with minimal effects on reaction time. The
lack of cognitive impairment after risperidone in this
study is likely due to the low dose used (with predicted
D2 occupancy of 50 %). We and others have reported that
single doses of risperidone at 2-mg impair reaction time
and performance in healthy volunteers (Koychev et al.
2012). However, studies in clinical populations have also
failed to demonstrate a superiority of aripiprazole over
risperidone for cognitive functioning (Khanna et al.
2013, 2014). This suggests that there are protective fac-
tors associated with risperidone’s mode of action that
compensate for its high-affinity D2 blockade. Although
both drugs release PFC dopamine (due to their
serotinergic actions), risperidone may do this to a greater
degree given its higher 5-HT2A receptor affinity. Reduced
CEs after risperidone may reflect a combination of in-
creased dopamine release acting on D1 receptors with in-
sufficient D2 blockade to interfere with performance.
Computational accounts suggest that D1 receptors in-
crease signal and reduce noise through simultaneously
enhancing glutamatergic maintenance of representations
while enhancing GABA surround inhibition (Durstewitz
and Seamans 2002; Williams and Castner 2006). D1-me-
diated improved signal to noise could thus account for the
improved performance and the trend for reduced cortical
BOLD response after risperidone—the latter reflecting
more efficient cortical processing. Indeed, dopamine-
releasing drugs reduce PFC metabolic demand and
BOLD signal in healthy volunteers during the perfor-
mance of cognitive tasks, both in the context of improved
performance and in the absence of a performance effect
(Mattay et al. 2003; Mehta et al. 2000; Tipper et al. 2005;
Volkow et al. 2008).
Direct actions at serotonin receptors
A reason for the lack of performance differences between
aripiprazole and risperidone (and the lack of differences
in cognitive effects found clinically) could be the seroto-
nergic actions of risperidone. The effects of 5-HT2A an-
tagonists on neuronal activity appear to be similar to that
of D2 agonism of reducing pyramidal and interneuron
activity to decrease signal to noise during delayed re-
sponse tasks (Williams et al. 2002). Direct application
of a 5-HT2A receptor antagonist into the PFC reduces
impulsive responding in rats (Winstanley et al. 2003);
therefore, risperidone may be reducing commission er-
rors via a reduction in impulsivity. A recent computation-
al model suggests that 5-HT1A receptor activation has
functional actions within the PFC during working mem-
ory, again similar to effects expected from D2 activation
(Cano-Colino et al . 2013). Therefore, some of
aripiprazole’s fMRI and behavioural effects may be the
result of a combination of D2 agonism, 5-HT2A antago-
nism and 5-HT1A agonism.
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Correlations between behavioural data and BOLD signals
No positive or negative correlations were found between task
performance and activity within the DLPFC. A likely reason
is that each drug affects several neural and cognitive processes
that influence performance which lack a final common,
performance-related effect on DLPFC neuronal activity and
resultant BOLD signal. Risperidone appeared to increase neu-
ral efficiency in the DLPFC since reduced activation was as-
sociated with enhanced performance, whereas aripiprazole ap-
peared to increase the recruitment of DLPFC neurons to aid
performance. The n-back task requires the execution of nu-
merous cognitive operations, and therefore different strategies
are likely to be used by different individuals to complete the
task, which could explain why correlations were not found
(Rypma et al. 2006). Furthermore, ceiling effects may have
resulted in insufficient performance variations to allow for
correlations to be found.
Limitations
The main limitation of this study is the low sample size which
resulted in low statistical power. This may have contributed to
the majority of the performance findings being of only trend-
level significance. Ceiling effects may also have constrained
detection of performance-enhancing effects of aripiprazole.
Indeed, other studies have reported drug-induced behavioural
differences in healthy volunteers only in the 3-back version of
the task (Mattay et al. 2000, 2003). Similarly, near-perfect
accuracy in the controls reduced the possibility of detecting
improved accuracy after drug treatment. Nevertheless, the da-
ta suggest the drugs may improve performance in different
ways—aripiprazole increased arousal (faster reaction times),
whereas risperidone reduced commission errors but had a re-
duced benefit on arousal.
Another limitation associated with the low statistical power
of the study may be that effects meeting statistical significance
(such as the fMRI effects in this study) may represent an
overestimation of the ‘true’ effect (Button et al. 2013).
The use of healthy volunteers rather than schizophrenia
patients could be seen as a limitation. However, risperidone
has been shown to both improve (Green et al. 1997) and im-
pair (Reilly et al. 2006, 2007) performance of a working mem-
ory task in schizophrenia patients. The contrasting results are
likely to have been due to differences, possibly unknown, in
illness and medication status of the patients. Such confounds
are by-passed in experiments in healthy volunteers.
Another potential limitation is that low doses of the study
drugs were used to minimise side effects, and therefore study
findings may not be applicable to the recommended doses for
the treatment of schizophrenia. As discussed, there appears to
bemarkedly different effects of aripiprazole and risperidone in
healthy volunteers, depending upon the dose used. Therefore,
it is quite possible that any beneficial effects of these drugs at
the doses used in this study may disappear at recommended
therapeutic doses, possibly explaining the limited effects of
these drugs on working memory in a study of schizophrenia
patients (Riedel et al. 2010). However, 5 mg of aripiprazole
was shown to significantly reduce negative symptoms in a
double-blind placebo controlled study in acutely relapsing
schizophrenia patients (Cutler et al. 2006). Furthermore, low
doses of aripiprazole and risperidone are efficacious as adjunct
treatments for major depressive disorder, an indication for
which aripiprazole is FDA-approved (Berman et al. 2007;
Mahmoud et al. 2007; Marcus et al. 2008; Terao 2008).
Therefore, the doses used in the study have clinically signifi-
cant effects that may be mediated by the prefrontal actions
demonstrated in this study. Although the degree to which the
single dose used in the current study can be applicable to
effects observed after repeated dosing is unknown, we feel
that the finding that acute low doses of antipsychotic drugs
do not impair but may potentially enhance cognitive function
is of clinical interest.
Conclusion
Aripiprazole increased DLPFC activation during the n-back
task, and this was associated with a trend for faster perfor-
mance and improved discriminability compared to placebo.
Risperidone also tended to improve discriminability and re-
duced incorrect responding which was associated with a trend
for reduced recruitment of the DLPFC compared to placebo.
The results are compatible with computational models accord-
ing to which (i) partial D2 agonist effects of aripiprazole would
enhance working memory capacity and thus processing speed
whereas (ii) D2 receptor blockade after risperidone together
with increased dopamine release onto D1 receptors would en-
hance signal to noise and thus cortical efficiency and perfor-
mance accuracy. Probably more complex interactions between
dopamine and serotonin play a role in the contrasting actions
of the drugs.
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